1. bookVolume 53 (2016): Issue 2 (December 2016)
Zeitschriftendaten
License
Format
Zeitschrift
Erstveröffentlichung
17 Aug 2013
Erscheinungsweise
2 Hefte pro Jahr
Sprachen
Englisch
access type Open Access

A comparison between the continual reassessment method and D-optimum design for dose finding in phase I clinical trials

Online veröffentlicht: 10 Dec 2016
Seitenbereich: 69 - 82
Zeitschriftendaten
License
Format
Zeitschrift
Erstveröffentlichung
17 Aug 2013
Erscheinungsweise
2 Hefte pro Jahr
Sprachen
Englisch

The continual reassessment method is a model-based procedure, described in the literature, used to determine the maximum tolerated dose in phase I clinical trials. The maximum tolerated dose can also be found under the framework of D-optimum design, where information is gathered in such a way so that asymptotic variability in the parameter estimates in minimised. This paper investigates the two methods under some realistic settings to explore any potential differences between them. Simulation studies for six plausible dose-response scenarios show that D-optimum design can work well in comparison with the continual reassessment method in many cases. The D-optimum design is also found to allocate doses from the extremes of the design region to the patients in a trial.

Atkinson A.C., Fedorov V.V., Herzberg A.M., Zhang R. (2014): Elemental information matrices and optimal experimental design for generalized regression models. Journal of Statistical Planning and Inference 144(1): 81–91.Search in Google Scholar

Babb J., Rogatko A., Zacks S. (1998): Cancer phase I clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine 17(10): 1103–1120.Search in Google Scholar

Chernoff H. (1953): Locally optimal designs for estimating parameters. The Annals of Mathematical Statistics 24(4): 586–602.Search in Google Scholar

Collins J.M., Grieshaber C.K., Chabner B.A. (1990): Pharmacologically guided phase I clinical trials based upon preclinical drug development. Journal of the National Cancer Institute 82(16): 1321–1326.Search in Google Scholar

Dixon W.J., Mood A.M. (1948): A method for obtaining and analyzing sensitivity data. Journal of the American Statistical Association 43(241): 109–126.Search in Google Scholar

Goodman S.N., Zahurak M.L., Piantadosi S. (1995): Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 14(11): 1149–1161.Search in Google Scholar

Korn E.L., Midthune D., Chen T.T., Rubinstein L.V., Christian M.C., Simon R.M. (1994): A comparison of two phase I trial designs. Statistics in Medicine 13(18): 1799–1806.Search in Google Scholar

Le Tourneau C., Lee J.J., Siu L.L. (2009): Dose escalation methods in phase I cancer clinical trials. Journal of the National Cancer Institute 101(10): 708–720.Search in Google Scholar

Leung D.H.Y., Wang Y.G. (2001): Isotonic designs for phase I trials. Controlled Clinical Trials 22(2): 126–138.Search in Google Scholar

Lévy V., Zohar S., Porcher R., Chevret S. (2001): Alternate designs for conduct and analysis of phase I cancer trials. Blood 98(4): 1275–1275.Search in Google Scholar

O’Quigley J., Pepe M., Fisher L. (1990): Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46(1): 33–48.Search in Google Scholar

O’Quigley J., Shen L.Z. (1996): Continual reassessment method: A likelihood approach. Biometrics 52(2): 673–684.Search in Google Scholar

O’Quigley J., Zohar S. (2006): Experimental designs for phase I and phase I/II dose-finding studies. British Journal of Cancer 94(5): 609–613.Search in Google Scholar

Reiner E., Paoletti X., O’Quigley J. (1999): Operating characteristics of the standard phase I clinical trial design. Computational Statistics and Data Analysis 30(3): 303–315.Search in Google Scholar

Simon R., Rubinstein L., Arbuck S.G., Christian M.C., Freidlin B., Collins J. (1997): Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 89(15): 1138–1147.Search in Google Scholar

Storer B.E. (1989): Design and analysis of phase I clinical trials. Biometrics 45(3): 925–937.Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo